SecBot SecBot
PRESS-RELEASE ·Filed Mar 24, 2026

PDSB

PDS Biotechnology Corporation
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the upcoming earnings call on March 30 for actual financial results and clinical development updates, which could move the stock given the company's small market cap.

DirectionNeutral
Confidencelow
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.6350
T+0 close · Mar 24, 2026 · via day close
Latest settled
+49.32%
T+60 · $0.9482
Vs SPY
+35.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 25 $0.6350entry
  2. T+1 · 8mo ago +0.79%α +2.56% · $0.6400
  3. T+5 · 8mo ago −4.57%α −4.32% · $0.6060
  4. T+20 · 7mo ago +46.14%α +38.28% · $0.9280
  5. T+60 · 5mo ago +49.32%α +35.87% · $0.9482
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology announced it will report its Q4 and full-year 2025 financial results and provide a clinical update on March 30, 2026. The press release contains no actual financial or operational data, only a notification of an upcoming earnings call.

Key Facts

  • PDS Biotech will report financial results for Q4 and full-year 2025 on March 30, 2026.
  • The announcement includes a clinical programs and corporate update.
  • No financial figures, guidance, or operational results were disclosed in this release.

Financial Impact

No financial data disclosed

Risk Factors

  • Lack of disclosed data limits immediate trading utility.
  • Biotech stocks with no revenue are highly sensitive to clinical trial updates, which may be positive or negative.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261723

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 24, 2026